Synergistic Inhibition of Hepatocellular Carcinoma Growth via Combined mTOR Blockade and Microtubule Disruption
Year: 2025
Type: article
Abstract: Hepatocellular carcinoma (HCC) poses considerable therapeutic challenges, given that standard chemotherapies offer only restricted benefit. The mammalian target of rapamycin/sirolimus (mTOR) and microtubules represent two major druggable vulnerabilities in HCC. In this work, we demonstrated that concurrent mTOR inhibition with mTOR inhibitors (everolimus and sirolimus) and the microtubule inhibitor vinorelbine yielded outcomes superior to those of single-agent regimens in HCC PDX models. Our dat
DOI: 10.51847/3w32mqtxb8
Institutions: Universidad de Granada, Universidad de Sevilla
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7161651344
